Fig. 1From: A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II studyWaterfall plot analysis of the best overall response in the intention to treat set. CR complete response; PR partial response; SD stable disease; PD progressive diseaseBack to article page